Semaglutide Results: Week-by-Week Timeline

The first four weeks at 0.25 mg weekly are designed to build tolerance to GLP-1 effects, not to produce weight loss. The standard Wegovy titration starts at 0.25 mg for 4 weeks, moves to 0.5 mg for 4 weeks, then 1.0 mg, 1.7 mg, and finally 2.4 mg maintenance.

What to expect in weeks 1 to 4: - 0 to 2 pounds of weight change, mostly from water shifts - Mild appetite suppression starts around day 3 to 5 of the first injection - First side effects (nausea, fullness, fatigue) peak around day 2 to 3 post-injection and fade before the next dose - Subtle changes in food preferences ("food noise" quieting down) - Possible mild GI effects: burping, soft stools, or constipation

What is happening biologically: Semaglutide reaches steady state plasma levels around week 4 to 5 of consistent dosing. During titration, plasma levels are building; effects are real but modest. GLP-1 receptors in your gut, pancreas, and hypothalamus are adapting to chronic signaling.

Common mistakes in weeks 1 to 4: - Weighing daily and panicking when the scale does not move - Increasing dose faster than the titration schedule (provider-ordered dose bumps before week 4 are usually a mistake) - Eating the same portions you did before because appetite suppression feels mild - Skipping the 4-week hold and thinking "I tolerate it well, let me jump to 1.0 mg"

What you should do: - Weigh weekly at the same time, same condition - Start tracking protein intake (target 1.0 to 1.6 g/kg lean body mass) - Begin or maintain 2 to 3 resistance training sessions per week; muscle preservation starts day 1 - Photograph your starting point (front, side, back) for the later phases when photos show what the scale may not

For injection technique, see how to inject peptides and semaglutide mixing chart.

This is when weight loss becomes visible to you and to others. You should be at 0.5 mg (weeks 5-8) then 1.0 mg (weeks 9-12) per the standard titration. Some providers extend each stage to 5 or 6 weeks.

Expected results by week 12: - STEP-1 trial data at 12 weeks: ~5% weight loss (about 11 lbs from 231-lb baseline) - Real-world data at 12 weeks: 4 to 7 lbs, slower due to lower effective doses - Clear reduction in hunger and craving intensity - Appetite suppression starts to feel more sustained (no longer just day 1-3 of the week) - Subjective energy may dip around week 6-8 as weight loss accelerates (manage with protein and sleep)

Body composition changes: - First 2 to 4 lbs of loss is often water and glycogen depletion - After that, roughly 70% fat / 30% lean tissue loss is typical without resistance training - With resistance training and adequate protein: closer to 85% fat / 15% lean - Waist circumference often drops faster than overall weight

Typical side effect trajectory: - Week 5: bump to 0.5 mg often triggers 2-3 days of nausea - Weeks 6-8: side effects plateau, most people feel "normalized" - Week 9: bump to 1.0 mg triggers another 2-3 days of increased nausea - Weeks 10-12: side effects settle at this new dose

Signs you are on track: - Steady weight loss of 0.5 to 1.5 lbs per week - Noticeable fullness from smaller portions - Less obsessive food thinking - Jeans feeling looser even before scale shows major change

Signs of a problem (call your provider): - No weight change over 4 weeks at 1.0 mg (dose may need to escalate) - Persistent vomiting for more than 48 hours after a dose - Severe upper abdominal pain (rule out pancreatitis) - Rapid weight loss greater than 2% per week (may indicate muscle wasting)

For troubleshooting a stalled start, see not losing weight on semaglutide. For side effect management, see how to relieve nausea from semaglutide and does semaglutide cause nausea.

This phase is when most of your total weight loss happens. You should be moving from 1.0 mg to 1.7 mg (weeks 13-16) to 2.4 mg maintenance (weeks 17+).

Expected results: - STEP-1 trial at week 28: approximately 10% body weight loss (23 lbs from 231-lb baseline) - Real-world data at week 28: 8 to 12% body weight loss - Weekly loss rate: 1 to 2 lbs per week consistently - Cumulative loss from baseline: 15 to 35 lbs depending on starting weight

What changes in this phase: - Visible change in face shape, clothing fit, and posture - Muscle definition becomes visible if you have been training - Cardiovascular fitness improves (lower resting heart rate, easier breathing at activity) - Blood pressure often drops 5-15 mmHg from baseline - HbA1c drops 0.5 to 1.5% if you are diabetic or pre-diabetic

Body composition gets serious: Without intervention, the rate of muscle loss accelerates during rapid weight loss. This phase is where resistance training and protein become critical. - Protein target: 1.6 to 2.0 g/kg lean body mass per day - Resistance training: 3 to 4 sessions per week, progressive overload - Prioritize sleep: 7 to 9 hours; growth hormone release during deep sleep protects muscle

Psychological changes to watch: - "Food noise" reduction is most dramatic here; some patients report surprise at how quiet their thinking becomes - Social eating situations become easier (less temptation) or harder (less reward) - Body dysmorphia risk: seeing progress often reveals new insecurities - For mood effects, see can semaglutide cause depression

Common plateau at week 16-20: Many people experience a 2-3 week scale stall around this point. Causes: - Glycogen repletion (temporary water retention) - Muscle gain from new training (offsets fat loss on scale) - Adaptive thermogenesis (metabolic rate drops 5-10%) - Hidden calorie creep as food tolerance returns

Fixes: increase protein, add 2 more resistance training sessions, audit liquid calories, be patient. Plateaus of 2-3 weeks are normal; real stalls are 4+ weeks.

By now you are at your maintenance dose (typically 2.4 mg weekly) and settled into routine. Results slow but do not stop.

Expected weekly progress: - 0.5 to 1 pound per week (down from 1-2 in the peak phase) - Cumulative: another 10-20 pounds over 24 weeks - At week 52 (1 year): total loss of 13-16% body weight typical in STEP-1

What gets harder: - Motivation drops as results slow - Side effects no longer dramatic, so the drug feels "less active" - Appetite partially returns; you can eat more than in month 3 - Compensatory behaviors increase if not monitored (bigger portions, more snacks)

What gets easier: - Habits are now routine; injection day, meal prep, and training all autopilot - Body composition continues to improve even when scale moves slowly - Cardiovascular markers (lipids, blood pressure, HbA1c) keep improving - Psychological relationship with food stabilizes

Common issues in months 8-12: - Muscle loss becomes obvious. If you have skipped resistance training for weeks, you will see loose skin, reduced strength, and a "skinny-fat" look. - Rebound eating during stressful periods. Job changes, holidays, illness can derail consistency. - Plateaus longer than 4 weeks. See why am I not losing weight on tirzepatide (same framework applies to semaglutide).

Medical check-ins: - Full blood panel (lipids, liver, kidney function, HbA1c) at month 6 and 12 - Weight trend review with provider every 3 months - DEXA scan or similar body composition check at 6 and 12 months if you have access

For long-term outcomes data, see tirzepatide maintenance dose after weight loss (transferable to semaglutide) and how long does semaglutide stay in your system.

The STEP-1 trial measured weight loss out to week 68. By this point, the average trajectory is flat. Real people often hit their plateau earlier, around weeks 40-52.

Expected status at week 68: - STEP-1 trial: 14.9% total weight loss maintained - Real-world: 10-14% maintained in consistent adherers - Plateau is pronounced; 2-3 week stalls become 6-8 week stalls - Body composition continues to improve if training continues - Most dramatic "after" photos are taken in this window

The three-way decision at week 68:

1. 1.Continue on semaglutide indefinitely. Data from post-trial follow-up shows that stopping semaglutide leads to regain of most lost weight within 2 years. Continuing maintains the loss. This is the most common choice for patients with obesity as a chronic disease.

1. 1.Switch to a more potent drug (tirzepatide). If weight loss has plateaued and you still have meaningful weight to lose, tirzepatide (22.5% loss in SURMOUNT-1 at 72 weeks) may push further. Semaglutide-to-tirzepatide transitions are common and well-tolerated. See semaglutide to tirzepatide conversion.

1. 1.Taper off and maintain with lifestyle. Requires robust protein, resistance training, sleep, and portion control. Highest rebound risk. Works for a minority of patients but is the minority outcome. For cautions around this path, see tirzepatide maintenance dose after weight loss (the pharmacology is analogous).

What most patients get wrong in month 12+: - Treating the plateau as failure. Your body is defending its new setpoint; that is biology, not failure. - Escalating dose beyond 2.4 mg (there is no 3.2 mg clinical benefit) - Restricting calories to push through the plateau; this accelerates muscle loss with minimal additional fat loss - Stopping abruptly without a maintenance plan

For comparison with other long-term weight loss drugs, see retatrutide vs tirzepatide and cagrilintide weight loss dosage.

STEP-1 is the reference trial, but your trajectory may look different. Common reasons:

Slower titration than trial protocol. Real-world providers sometimes extend the 0.25 mg and 0.5 mg phases to 5 or 6 weeks to reduce side effects. This delays the peak-loss phase by 4 to 6 weeks.

Lower maintenance dose. Some patients cannot tolerate 2.4 mg and maintain on 1.0 or 1.7 mg. Lower doses produce proportionally less weight loss, usually 5 to 10% instead of 14.9%.

Interruptions from side effects or supply. Every week off semaglutide slows the timeline by approximately 1 to 1.5 weeks of equivalent progress.

Starting weight matters. Patients with BMI > 40 often lose more absolute pounds but similar percentage. Patients with BMI 27 to 32 have less to lose and plateau sooner.

Age and sex effects. Men typically lose slightly faster than women in the first 12 weeks. Post-menopausal women and older patients often have slower early loss but similar total loss at 68 weeks.

Diabetes status. Diabetic patients lose less weight on semaglutide than non-diabetic patients (roughly 10% vs 15% at 68 weeks). This is consistent across GLP-1 trials.

Lifestyle factors. Resistance training + protein intake produces 20 to 30% more lean-mass preservation and better body composition at the same scale weight.

Compounded vs brand product variability. Compounded semaglutide quality varies. A sub-potent compounded product extends your timeline meaningfully. See is compound tirzepatide safe for compounded product considerations (same logic applies to semaglutide).

For the full trial data, see semaglutide before and after. For maximum-efficacy alternatives, see retatrutide vs tirzepatide.